Literature DB >> 35460242

Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management.

Gaetano Santulli1, Xujun Wang1, Pasquale Mone1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35460242      PMCID: PMC9366633          DOI: 10.1093/ehjcvp/pvac029

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


× No keyword cloud information.
  5 in total

1.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

2.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Authors:  Stefan D Anker; Javed Butler; Gerasimos Filippatos; João P Ferreira; Edimar Bocchi; Michael Böhm; Hans-Peter Brunner-La Rocca; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure-Valenzuela; Nadia Giannetti; Juan Esteban Gomez-Mesa; Stefan Janssens; James L Januzzi; Jose R Gonzalez-Juanatey; Bela Merkely; Stephen J Nicholls; Sergio V Perrone; Ileana L Piña; Piotr Ponikowski; Michele Senni; David Sim; Jindrich Spinar; Iain Squire; Stefano Taddei; Hiroyuki Tsutsui; Subodh Verma; Dragos Vinereanu; Jian Zhang; Peter Carson; Carolyn Su Ping Lam; Nikolaus Marx; Cordula Zeller; Naveed Sattar; Waheed Jamal; Sven Schnaidt; Janet M Schnee; Martina Brueckmann; Stuart J Pocock; Faiez Zannad; Milton Packer
Journal:  N Engl J Med       Date:  2021-08-27       Impact factor: 176.079

3.  Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.

Authors:  Pasquale Mone; Angela Lombardi; Jessica Gambardella; Antonella Pansini; Gaetano Macina; Maria Morgante; Salvatore Frullone; Gaetano Santulli
Journal:  Diabetes Care       Date:  2022-05-01       Impact factor: 17.152

Review 4.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Paul A Heidenreich; Biykem Bozkurt; David Aguilar; Larry A Allen; Joni J Byun; Monica M Colvin; Anita Deswal; Mark H Drazner; Shannon M Dunlay; Linda R Evers; James C Fang; Savitri E Fedson; Gregg C Fonarow; Salim S Hayek; Adrian F Hernandez; Prateeti Khazanie; Michelle M Kittleson; Christopher S Lee; Mark S Link; Carmelo A Milano; Lorraine C Nnacheta; Alexander T Sandhu; Lynne Warner Stevenson; Orly Vardeny; Amanda R Vest; Clyde W Yancy
Journal:  Circulation       Date:  2022-04-01       Impact factor: 39.918

5.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Authors:  Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Peter Carson; James Januzzi; Subodh Verma; Hiroyuki Tsutsui; Martina Brueckmann; Waheed Jamal; Karen Kimura; Janet Schnee; Cordula Zeller; Daniel Cotton; Edimar Bocchi; Michael Böhm; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure; Nadia Giannetti; Stefan Janssens; Jian Zhang; Jose R Gonzalez Juanatey; Sanjay Kaul; Hans-Peter Brunner-La Rocca; Bela Merkely; Stephen J Nicholls; Sergio Perrone; Ileana Pina; Piotr Ponikowski; Naveed Sattar; Michele Senni; Marie-France Seronde; Jindrich Spinar; Iain Squire; Stefano Taddei; Christoph Wanner; Faiez Zannad
Journal:  N Engl J Med       Date:  2020-08-28       Impact factor: 176.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.